GLP-1-话题@MedSci

#GLP-1#

114篇内容 | 4074人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1422733, encodeId=4cc21422e33e7, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=喜大普奔！降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国, objectType=article, longId=161211, objectId=849816121109, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=849816121109, replyNumber=0, likeNumber=84, createdTime=2019-02-28, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=849816121109, moduleTitle=喜大普奔！降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=849816121109)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422732, encodeId=f4b61422e326e, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=礼来降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国, objectType=article, longId=161199, objectId=4d8e16119952, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d8e16119952, replyNumber=0, likeNumber=89, createdTime=2019-02-28, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d8e16119952, moduleTitle=礼来降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d8e16119952)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422731, encodeId=90221422e31e1, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=BCPT：GLP-1受体激动剂除了降糖，还能护肝，专家怎么看？, objectType=article, longId=159719, objectId=117f159e19e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=117f159e19e4, replyNumber=0, likeNumber=76, createdTime=2019-02-11, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=117f159e19e4, moduleTitle=BCPT：GLP-1受体激动剂除了降糖，还能护肝，专家怎么看？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=117f159e19e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422730, encodeId=1e7b1422e3011, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Hepatology：丁酸钠可以通过上调肝脏GLP-1R表达减少高脂饮食诱导的非酒精性脂肪性肝炎, objectType=article, longId=158523, objectId=8bfb158523b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8bfb158523b9, replyNumber=0, likeNumber=54, createdTime=2019-01-22, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8bfb158523b9, moduleTitle=Hepatology：丁酸钠可以通过上调肝脏GLP-1R表达减少高脂饮食诱导的非酒精性脂肪性肝炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8bfb158523b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422729, encodeId=d6471422e2915, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=BMJ：DPP-4抑制剂以及GLP-1激动剂或导致糖尿病患者胆管癌风险增加, objectType=article, longId=155614, objectId=db9d15561414, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db9d15561414, replyNumber=0, likeNumber=51, createdTime=2018-12-13, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db9d15561414, moduleTitle=BMJ：DPP-4抑制剂以及GLP-1激动剂或导致糖尿病患者胆管癌风险增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db9d15561414)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422728, encodeId=4e0a1422e287d, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Lancet：新型GIP/GLP-1R双靶点降糖新药II期数据惊艳，HbA1c下降达2.4%, objectType=article, longId=150492, objectId=25fa15049273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25fa15049273, replyNumber=0, likeNumber=61, createdTime=2018-10-08, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25fa15049273, moduleTitle=Lancet：新型GIP/GLP-1R双靶点降糖新药II期数据惊艳，HbA1c下降达2.4%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25fa15049273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422727, encodeId=a2ac1422e27c1, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=礼来公司收购Chugai在研口服非肽类GLP-1受体激动剂用于治疗糖尿病, objectType=article, longId=149977, objectId=93781499e7e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93781499e7e4, replyNumber=0, likeNumber=87, createdTime=2018-09-30, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93781499e7e4, moduleTitle=礼来公司收购Chugai在研口服非肽类GLP-1受体激动剂用于治疗糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93781499e7e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422726, encodeId=2e631422e26e4, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Diabetes：GLP-1与胃饥饿素协同调节葡萄糖耐受, objectType=article, longId=147117, objectId=b96c14e117b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b96c14e117b7, replyNumber=0, likeNumber=57, createdTime=2018-08-22, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b96c14e117b7, moduleTitle=Diabetes：GLP-1与胃饥饿素协同调节葡萄糖耐受, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b96c14e117b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422725, encodeId=ed021422e25d8, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=全球糖尿病超长效GLP-1抗体激动剂在中国获批临床, objectType=article, longId=146518, objectId=2f051465185b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f051465185b, replyNumber=0, likeNumber=93, createdTime=2018-08-14, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f051465185b, moduleTitle=全球糖尿病超长效GLP-1抗体激动剂在中国获批临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f051465185b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422724, encodeId=96f21422e24ae, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Hypertension：2型糖尿病患者长期应用短效GLP-1RA对系统血流动力学的影响, objectType=article, longId=146095, objectId=6bd214609513, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bd214609513, replyNumber=0, likeNumber=73, createdTime=2018-08-09, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bd214609513, moduleTitle=Hypertension：2型糖尿病患者长期应用短效GLP-1RA对系统血流动力学的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bd214609513)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422723, encodeId=5e471422e23ff, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=GLP-1受体激动剂临床应用专家指导意见, objectType=article, longId=142197, objectId=3f2414219e1b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f2414219e1b, replyNumber=0, likeNumber=33, createdTime=2018-07-03, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f2414219e1b, moduleTitle=GLP-1受体激动剂临床应用专家指导意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f2414219e1b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422722, encodeId=44ac1422e2210, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Lancet：GLP-1及胰高血糖素受体双重激动剂MEDI0382可改善II型糖尿病患者体重, objectType=article, longId=141602, objectId=62b1141602a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62b1141602a2, replyNumber=0, likeNumber=58, createdTime=2018-06-27, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62b1141602a2, moduleTitle=Lancet：GLP-1及胰高血糖素受体双重激动剂MEDI0382可改善II型糖尿病患者体重, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62b1141602a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422721, encodeId=c89d1422e2187, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Stem Cell Res Ther：Azoramide通过抑制GLP-1受体-PKA-β-连环蛋白途径来促进脂肪生成以抵抗骨生成, objectType=article, longId=132346, objectId=7d1a13234672, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d1a13234672, replyNumber=0, likeNumber=57, createdTime=2018-03-15, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d1a13234672, moduleTitle=Stem Cell Res Ther：Azoramide通过抑制GLP-1受体-PKA-β-连环蛋白途径来促进脂肪生成以抵抗骨生成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d1a13234672)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422720, encodeId=601c1422e20f6, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Lancet Diabetes Endo：GLP-1受体激动剂是否有心血管保护作用？, objectType=article, longId=131617, objectId=7fb513161eba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fb513161eba, replyNumber=0, likeNumber=65, createdTime=2018-03-08, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fb513161eba, moduleTitle=Lancet Diabetes Endo：GLP-1受体激动剂是否有心血管保护作用？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fb513161eba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422719, encodeId=c7391422e19a6, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Am Heart J：胰岛素治疗的2型糖尿病患者添加GLP-1RA喜忧参半, objectType=article, longId=131184, objectId=80e513118486, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80e513118486, replyNumber=0, likeNumber=47, createdTime=2018-03-03, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80e513118486, moduleTitle=Am Heart J：胰岛素治疗的2型糖尿病患者添加GLP-1RA喜忧参半, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80e513118486)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422718, encodeId=b82e1422e181b, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Diabetes Obes Metab：T2DM患者联合服用Canagliflozin与GLP-1RA的疗效和安全性分析！, objectType=article, longId=131067, objectId=333a13106e16, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=333a13106e16, replyNumber=0, likeNumber=37, createdTime=2018-03-02, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=333a13106e16, moduleTitle=Diabetes Obes Metab：T2DM患者联合服用Canagliflozin与GLP-1RA的疗效和安全性分析！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=333a13106e16)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422717, encodeId=5bd01422e17c2, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=J Clin Lipidol：血脂异常的T2DM患者：GLP-1RAs+他汀是个不错的选择？, objectType=article, longId=129344, objectId=1d9d12934457, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d9d12934457, replyNumber=0, likeNumber=69, createdTime=2018-02-10, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d9d12934457, moduleTitle=J Clin Lipidol：血脂异常的T2DM患者：GLP-1RAs+他汀是个不错的选择？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d9d12934457)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422716, encodeId=0f711422e1681, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Diabetes：利用靶向RNAi筛查探寻调控胰腺β细胞GLP-1R的内吞转运因子——治疗T2D的新的药物靶点。, objectType=article, longId=125269, objectId=94b412526921, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94b412526921, replyNumber=0, likeNumber=64, createdTime=2018-01-03, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94b412526921, moduleTitle=Diabetes：利用靶向RNAi筛查探寻调控胰腺β细胞GLP-1R的内吞转运因子——治疗T2D的新的药物靶点。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94b412526921)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422715, encodeId=4ba01422e15e9, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Diabetes Care：2型糖尿病GLP-1 RA和DPP-4治疗：真实世界有效性数据为何比RCT差？, objectType=article, longId=124969, objectId=962b12496943, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=962b12496943, replyNumber=0, likeNumber=62, createdTime=2017-12-30, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=962b12496943, moduleTitle=Diabetes Care：2型糖尿病GLP-1 RA和DPP-4治疗：真实世界有效性数据为何比RCT差？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=962b12496943)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422714, encodeId=fa151422e1446, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Hepatology：GLP-1受体激动剂改善脂肪肝时肝脏内质网应激新机制, objectType=article, longId=124117, objectId=11df12411e88, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11df12411e88, replyNumber=0, likeNumber=169, createdTime=2017-12-22, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11df12411e88, moduleTitle=Hepatology：GLP-1受体激动剂改善脂肪肝时肝脏内质网应激新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11df12411e88)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GLP-1

2020-05-29

yibei (审核中...)

前往app查看评论内容

#GLP-1#

喜大普奔！降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国

2019-02-28

yibei (审核中...)

前往app查看评论内容

#GLP-1#

礼来降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国

2019-02-28

yibei (审核中...)

前往app查看评论内容

#GLP-1#

BCPT：GLP-1受体激动剂除了降糖，还能护肝，专家怎么看？

2019-02-11

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Hepatology：丁酸钠可以通过上调肝脏GLP-1R表达减少高脂饮食诱导的非酒精性脂肪性肝炎

2019-01-22

yibei (审核中...)

前往app查看评论内容

#GLP-1#

BMJ：DPP-4抑制剂以及GLP-1激动剂或导致糖尿病患者胆管癌风险增加

2018-12-13

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Lancet：新型GIP/GLP-1R双靶点降糖新药II期数据惊艳，HbA1c下降达2.4%

2018-10-08

yibei (审核中...)

前往app查看评论内容

#GLP-1#

礼来公司收购Chugai在研口服非肽类GLP-1受体激动剂用于治疗糖尿病

2018-09-30

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Diabetes：GLP-1与胃饥饿素协同调节葡萄糖耐受

2018-08-22

yibei (审核中...)

前往app查看评论内容

#GLP-1#

全球糖尿病超长效GLP-1抗体激动剂在中国获批临床

2018-08-14

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Hypertension：2型糖尿病患者长期应用短效GLP-1RA对系统血流动力学的影响

2018-08-09

yibei (审核中...)

前往app查看评论内容

#GLP-1#

GLP-1受体激动剂临床应用专家指导意见

2018-07-03

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Lancet：GLP-1及胰高血糖素受体双重激动剂MEDI0382可改善II型糖尿病患者体重

2018-06-27

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Stem Cell Res Ther：Azoramide通过抑制GLP-1受体-PKA-β-连环蛋白途径来促进脂肪生成以抵抗骨生成

2018-03-15

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Lancet Diabetes Endo：GLP-1受体激动剂是否有心血管保护作用？

2018-03-08

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Am Heart J：胰岛素治疗的2型糖尿病患者添加GLP-1RA喜忧参半

2018-03-03

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Diabetes Obes Metab：T2DM患者联合服用Canagliflozin与GLP-1RA的疗效和安全性分析！

2018-03-02

yibei (审核中...)

前往app查看评论内容

#GLP-1#

J Clin Lipidol：血脂异常的T2DM患者：GLP-1RAs+他汀是个不错的选择？

2018-02-10

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Diabetes：利用靶向RNAi筛查探寻调控胰腺β细胞GLP-1R的内吞转运因子——治疗T2D的新的药物靶点。

2018-01-03

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Diabetes Care：2型糖尿病GLP-1 RA和DPP-4治疗：真实世界有效性数据为何比RCT差？

2017-12-30

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Hepatology：GLP-1受体激动剂改善脂肪肝时肝脏内质网应激新机制

2017-12-22

科室
- - 订阅+
  - 更多科室
工具
服务